 |
|
|
|
 |
A Phase I/II Study of the Tor Kinase Inhibitor AZD8055 in Patients with Advanced Solid Tumors, Lymphomas, or Endometrial Carcinoma
[Protocol 08-093]
- Full Title :
- A PHASE I/II, OPEN LABEL, MULTI-CENTRE STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PRELIMINARY EFFICACY OF THE TOR KINASE INHIBITOR AZD8055 ADMINISTERED ORALLY TO PATIENTS WITH ADVANCED SOLID TUMOURS, LYMPHOMAS, AND ENDOMETRIAL CARCINOMAS
- Purpose :
The purpose of this study is to find the highest dose of an investigational drug called AZD8055 that can be given safely in patients with advanced solid tumors, lymphoma, or endometrial cancer that has continued to grow despite standard treatment or for which no standard therapy exists. AZD8055 works by inhibiting mTOR, an important regulatory protein in a key signaling pathway that governs cancer cell growth and division. It is taken orally (by mouth).
- Eligibility :
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must have an advanced solid tumor, lymphoma, or endometrial cancer which does not respond to standard therapies, for which no standard therapies exist, or for which the investigator feels no other active therapy is required for the duration of the study.
- At least 3 weeks must have passed since completion of prior therapies and entry into the study, and patients must have recovered from any side effects.
- Patients must be age 18 or older.
For more information and to inquire about eligibility for this study, please contact Dr. Carol Aghajanian at 212-639-2252.
|
|
|
|
|
